Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2011-08-30
2011-08-30
Duffy, Patricia A (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C436S092000, C514S282000
Reexamination Certificate
active
08008457
ABSTRACT:
The structural design, preparative methods and chemical composition of two structural formulations of bivalent vaccines against morphine-heroin addiction (morphine-6-hemisuccinyl-EDC-TFCS-tetanus toxoid and 3-O-carboxymethylmorphine-EDC-TFCS-tetanus toxoid), are disclosed. These vaccines are suitable for human use in which they are capable of triggering the synthesis of polyclonal antibodies against morphine opiate and its structural analogue, heroin, through the repeated in vivo administration of these formulations, in active vaccination protocols, in pre-clinical studies in rodents. The active vaccination paradigm through which these immunogens trigger a humoral immune response consolidated with a long-term immunological memory, characterized by the presence of high titers of specific antibodies against these two drugs of abuse, is also disclosed. Furthermore, the present invention reveals the efficacy of these conjugate formulations for triggering a sustained immunoprotection against morphine and heroin addiction using an intravenous self-administration paradigm of these two opiate substances in the rodent. Finally, a discussion is also made on the potential future use of these immunoconjugates in active vaccination protocols for treating both morphine and heroin addiction in the humans.
REFERENCES:
patent: 1196955 (1998-10-01), None
patent: WO-92/03163 (1992-03-01), None
patent: WO-96/30049 (1996-10-01), None
patent: WO-98/14216 (1998-04-01), None
patent: WO-2004/076677 (2004-09-01), None
Nestler, Eric Neuropharmacology 47:24-32, 2002.
Akbarzadeh, Azim et al., “Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development,”Biotechnol. App. Biochem.,vol. 30:139-145 (1999).
Carrera, M. Rocio A. et al., “A second-generation vaccine protects against the psychoactive effects of cocaine,”PNAS,vol. 98(4):1988-1992 (2001).
Gebhart, G.F. et al., “Morphine-6-Hemisuccinate as a Narcotic Analgesic,”Life Sciences,vol. 18:829-836 (1976).
Heading, Christine E., “TA-CD Xenova,”IDrugs,vol. 5(11):1070-1074 (2002).
Pierce, “TFCS,” retrieved online at http://www.piercenet.com (1998).
Wainer, Bruce H. et al., “Morphine-3-Succinyl-Bovine Serum Albumin: An Immunogenic Hapten-Protein Conjugate,”Science,vol. 176(4039):1143-1145 (1972).
International Search Report for Application No. PCT/MX2005/000049, dated Jul. 11, 2006.
Written Opinion for Application No. PCT/MX2005/000049, dated Jul. 11, 2006.
Gelman Philippe Leff
Palma Benito Anton
DiGiorgio, Esq. Jeanne M.
Duffy Patricia A
Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz
Nelson Mullins Riley & Scarborough LLP
Sloper, Esq. Jill Gorny
LandOfFree
Process for the preparation and use of a bivalent vaccine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation and use of a bivalent vaccine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation and use of a bivalent vaccine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2785352